【摘要】 急性心肌梗死(acute myocardial infarction, AMI)及心力衰竭并发症的发病率和病死率在全世界仍然居高不下。经证实AMI后冠状动脉的早期再灌注是典型而有效的治疗方法,但侧支及心肌缺血再灌注损伤(myocardial ischemia reperfusion injury,MIRI)及相关的心脏保护机制尚不清楚。因此,研究触发和治疗MIRI病理生理学的相关新型分子靶点有重要意义。特别关注由分子药理学支持的MIRI的最新进展,以此简单阐述参与预防和抗心肌缺血再灌注损伤的最新分子靶点,以期为心肌缺血再灌注损伤的机制研究与新药研发提供思路。更多还原

【Abstract】 Worldwide morbidity and mortality of acute myocardial infarction(AMI) and related heart failure are still high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical and effective treatment at present, collateral myocardial ischemia reperfusion injury(MIRI) and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated molecular pharmacology in order to bring the poorly understood interrelationship among MIRI participant molecules up to date, as well as to identify findings that may facilitate the new drug of novel targets.更多还原